Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 590

1.

CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia.

von Tresckow J, Cramer P, Bahlo J, Robrecht S, Langerbeins P, Fink AM, Al-Sawaf O, Illmer T, Klaproth H, Estenfelder S, Ritgen M, Fischer K, Wendtner CM, Kreuzer KA, Stilgenbauer S, Böttcher S, Eichhorst BF, Hallek M.

Leukemia. 2018 Dec 19. doi: 10.1038/s41375-018-0313-8. [Epub ahead of print]

PMID:
30568174
2.

Management of unfit elderly patients with chronic lymphocytic leukemia.

Eichhorst B, Hallek M, Goede V.

Eur J Intern Med. 2018 Dec;58:7-13. doi: 10.1016/j.ejim.2018.02.001. Review.

PMID:
30527922
3.

On the architecture of translational research designed to control chronic lymphocytic leukemia.

Hallek M.

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):1-8. doi: 10.1182/asheducation-2018.1.1. Review.

PMID:
30504285
4.

Does Exercise Have a Preventive Effect on Secondary Lymphedema in Breast Cancer Patients Following Local Treatment? - A Systematic Review.

Baumann FT, Reike A, Hallek M, Wiskemann J, Reimer V.

Breast Care (Basel). 2018 Oct;13(5):380-385. doi: 10.1159/000487428. Epub 2018 May 3. Review.

PMID:
30498426
5.

Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia.

Al-Sawaf O, Bahlo J, Robrecht S, Fischer K, Herling CD, Hoechstetter M, Fink AM, von Tresckow J, Langerbeins P, Cramer P, Stilgenbauer S, Wendtner CM, Eichhorst B, Hallek M, Goede V.

Br J Haematol. 2018 Dec;183(5):727-735. doi: 10.1111/bjh.15604. Epub 2018 Nov 21.

PMID:
30460980
6.

Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab.

Langerak AW, Ritgen M, Goede V, Robrecht S, Bahlo J, Fischer K, Steurer M, Trněný M, Mulligan SP, Mey UJM, Trunzer K, Fingerle-Rowson G, Humphrey K, Stilgenbauer S, Böttcher S, Brüggemann M, Hallek M, Kneba M, van Dongen JJM.

Blood. 2018 Nov 19. pii: blood-2018-03-839688. doi: 10.1182/blood-2018-03-839688. [Epub ahead of print] No abstract available.

PMID:
30455380
7.

Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials.

Soumerai JD, Ni A, Xing G, Huang J, Furman RR, Jones J, Sharman JP, Hallek M, Adewoye AH, Dubowy R, Dreiling L, Zelenetz AD.

Leuk Lymphoma. 2018 Nov 8:1-9. doi: 10.1080/10428194.2018.1540782. [Epub ahead of print]

PMID:
30407886
8.

Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.

Fraser G, Cramer P, Demirkan F, Silva RS, Grosicki S, Pristupa A, Janssens A, Mayer J, Bartlett NL, Dilhuydy MS, Pylypenko H, Loscertales J, Avigdor A, Rule S, Villa D, Samoilova O, Panagiotidis P, Goy A, Pavlovsky MA, Karlsson C, Hallek M, Mahler M, Salman M, Sun S, Phelps C, Balasubramanian S, Howes A, Chanan-Khan A.

Leukemia. 2018 Oct 12. doi: 10.1038/s41375-018-0276-9. [Epub ahead of print]

PMID:
30315239
9.

Somatic alterations in circulating cell-free DNA of oesophageal carcinoma patients during primary staging are indicative for post-surgical tumour recurrence.

Pasternack H, Fassunke J, Plum PS, Chon SH, Hescheler DA, Gassa A, Merkelbach-Bruse S, Bruns CJ, Perner S, Hallek M, Büttner R, Bollschweiler E, Hölscher AH, Quaas A, Zander T, Weiss J, Alakus H.

Sci Rep. 2018 Oct 8;8(1):14941. doi: 10.1038/s41598-018-33027-4.

10.

New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance.

Pflug N, Cramer P, Robrecht S, Bahlo J, Westermann A, Fink AM, Schrader A, Mayer P, Oberbeck S, Seiler T, Zenz T, Dürig J, Kreuzer KA, Stilgenbauer S, Eichhorst B, Hallek M, Herling M, Hopfinger G.

Leuk Lymphoma. 2018 Sep 20:1-9. doi: 10.1080/10428194.2018.1488253. [Epub ahead of print]

PMID:
30234404
11.

[The 2017/2018 influenza season-business as usual? : A statement of medical societies].

Kochanek M, Böll B, Shimabukuro-Vornhagen A, Welte T, Wieland U, Pletz M, Hallek M, Fätkenheuer G, Salzberger B.

Internist (Berl). 2018 Sep 14. doi: 10.1007/s00108-018-0501-7. [Epub ahead of print] German. No abstract available.

PMID:
30218201
12.

[Individualized Treatment of Chronic Lymphocytic Leukemia (CLL)].

von Tresckow J, Hallek M, Eichhorst B.

Dtsch Med Wochenschr. 2018 Sep;143(18):1318-1324. doi: 10.1055/a-0550-2286. Epub 2018 Sep 10. German.

PMID:
30199912
13.

Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50Years or Older with Severe Aplastic Anemia.

Rice C, Eikema DJ, Marsh JCW, Knol C, Hebert K, Putter H, Peterson E, Deeg HJ, Halkes S, Pidala J, Anderlini P, Tischer J, Kroger N, McDonald A, Antin JH, Schaap NP, Hallek M, Einsele H, Mathews V, Kapoor N, Boelens JJ, Mufti GJ, Potter V, Pefault de la Tour R, Eapen M, Dufour C.

Biol Blood Marrow Transplant. 2018 Sep 5. pii: S1083-8791(18)30531-7. doi: 10.1016/j.bbmt.2018.08.029. [Epub ahead of print]

PMID:
30194027
14.

Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib.

Krause G, Hassenrück F, Hallek M.

Drug Des Devel Ther. 2018 Aug 21;12:2577-2590. doi: 10.2147/DDDT.S142406. eCollection 2018. Review.

15.

Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial.

Cramer P, von Tresckow J, Bahlo J, Robrecht S, Langerbeins P, Al-Sawaf O, Engelke A, Fink AM, Fischer K, Tausch E, Seiler T, Fischer von Weikersthal L, Hebart H, Kreuzer KA, Böttcher S, Ritgen M, Kneba M, Wendtner CM, Stilgenbauer S, Eichhorst B, Hallek M.

Lancet Oncol. 2018 Sep;19(9):1215-1228. doi: 10.1016/S1470-2045(18)30414-5. Epub 2018 Aug 13.

PMID:
30115596
16.

Der ältere Krebspatient - Herausforderungen im Krankenhaus und in der Praxis.

Bokemeyer C, Busse R, Engel J, Gebauer A, Hallek M, Heinemann V, Lüftner D, Wörmann B.

Oncol Res Treat. 2018;41 Suppl 3:2-26. doi: 10.1159/000490082. Epub 2018 Jul 26. No abstract available.

17.

Vorwort.

Hallek M, Bokemeyer C, Lüftner D, Weissinger F.

Oncol Res Treat. 2018;41 Suppl 3:1. doi: 10.1159/000491683. Epub 2018 Jul 26. No abstract available.

18.

Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer.

Golfmann K, Meder L, Koker M, Volz C, Borchmann S, Tharun L, Dietlein F, Malchers F, Florin A, Büttner R, Rosen N, Rodrik-Outmezguine V, Hallek M, Ullrich RT.

Oncogene. 2018 Oct;37(42):5682-5693. doi: 10.1038/s41388-018-0380-3. Epub 2018 Jul 3.

PMID:
29970903
19.

Effects of Kyusho Jitsu on Physical Activity-levels and Quality of Life in Breast Cancer Patients.

Strunk MA, Zopf EM, Steck J, Hamacher S, Hallek M, Baumann FT.

In Vivo. 2018 Jul-Aug;32(4):819-824. doi: 10.21873/invivo.11313.

20.

Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia.

Davids MS, Hallek M, Wierda W, Roberts AW, Stilgenbauer S, Jones JA, Gerecitano JF, Kim SY, Potluri J, Busman T, Best A, Verdugo ME, Cerri E, Desai M, Hillmen P, Seymour JF.

Clin Cancer Res. 2018 Sep 15;24(18):4371-4379. doi: 10.1158/1078-0432.CCR-17-3761. Epub 2018 Jun 12.

PMID:
29895707

Supplemental Content

Loading ...
Support Center